Danning Zhao, Qin Liu^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084736 - 13 August 2026

Abstract Cervical cancer, particularly its advanced stages, requires novel therapeutic paradigms. Cellular immunotherapy exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens. This review systematically evaluates four principal platforms under investigation: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. We critically analyze the preclinical rationale, clinical trial landscape, safety considerations, and manufacturing challenges for each modality. TIL therapy has achieved durable complete responses and an FDA Breakthrough Therapy designation. TCR-T cells enable precise targeting of intracellular viral epitopes but are HLA-restricted. CAR-T cells offer potent, MHC-independent recognition, yet face on-target/off-tumor More >

Emmanuel Naveen Raj^1,#, Chia-Jung Li^1,2,3,4,5,#, Shih-Hsuan Cheng¹, Su-Boon Yong^6,7, Zhi-Hong Wen^3,8, An-Jen Chiang^1,9,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079551 - 13 August 2026

Abstract Objectives: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) necessitate the discovery of novel biomarkers for prognostic and therapeutic advancement. This study aims to evaluate the clinical significance of ubiquitin-conjugating enzyme E2C (UBE2C) and its association with the tumor microenvironment (TME) in CESC. Methods: We meticulously sourced CESC data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO), leveraging cutting-edge techniques including single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics. Through multifaceted data analysis, we endeavored to unravel the intricate role and potential value of UBE2C in… More > Graphic Abstract

Oncology Research Editorial Office

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.088697 - 16 July 2026

Abstract This article has no abstract. More >

Pei-Yu Kao¹, Jie-Hong Chen², Kuo-Hu Chen^1,3,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078219 - 21 May 2026

Abstract Cervical cancer remains a major global health challenge despite advances in human papillomavirus (HPV) vaccination, screening, and treatment. Persistent infection with high-risk HPV types, particularly HPV16 and HPV18, is a necessary cause of cervical cancer; however, only a small fraction of infections progress to malignancy, indicating the importance of additional cofactors. Increasing evidence identifies estrogen signaling as a critical modifier of HPV-driven carcinogenesis. Estrogen acts synergistically with HPV oncogenes E6 and E7 to promote genomic instability, immune evasion, and tumor progression, largely through effects on the tumor microenvironment (TME). This review aims to clarify and… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.078461 - 19 January 2026

Abstract This article has no abstract. More >

Abdulrahman K. Sinno¹, Aisha Mustapha¹, Navya Nair¹, Simona Zaami², Lina De Paola², Valentina Billone³, Eleonora Conti³, Giuseppe Gullo^3,*, Pasquale Patrizio⁴

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072176 - 30 December 2025

Abstract Cervical cancer related to human papillomavirus (HPV) is a leading cause of cancer-related mortality among women worldwide. Cancer cells release fragments of their DNA, known as circulating tumor DNA (ctDNA), which can be detected in bodily fluids. A PubMed search using the terms “ctHPV” or “circulating tumor DNA” and “cervical cancer”, limited to the past ten years, identified 104 articles, complemented by hand-searching for literature addressing medico-legal implications. Studies were evaluated for relevance and methodological quality. Detection and characterization of circulating tumor HPV DNA (ctHPV DNA) have emerged as promising tools for assessing prognosis and More >

Min Ma^1,2,3,#, Zhuxiu Wang^4,#, Yan Cao⁴, Juanying Yang⁴, Zeliang Zhuang⁵, Linqian Shi^4,*, Qian Gao^4,*

BIOCELL, Vol.49, No.12, pp. 2399-2413, 2025, DOI:10.32604/biocell.2025.071255 - 24 December 2025

Abstract Objectives: Keratin 6A (KRT6A) has been implicated in the progression of multiple malignancies; however, its expression pattern and biological role in cervical cancer (CC) have not been elucidated. This study aims to investigate KRT6A expression in CC tissues and evaluate its effects on cellular proliferation, migration, and invasion, thereby assessing its potential as a biomarker and therapeutic target. Methods: Differentially expressed genes were screened from the Gene Expression Omnibus (GEO) dataset (GSE9750) using the thresholds |log2FC| > 2 and false discovery rate (FDR) < 0.05. Immunohistochemistry was performed to evaluate KRT6A protein expression in tumor… More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.12, pp. 4157-4157, 2025, DOI:10.32604/or.2025.075991 - 27 November 2025

Abstract This article has no abstract. More >

YUANLIN LIU^1,3, YAN LIU², YAN WANG², QIANG WANG², YAN YAN¹, DANDAN ZHANG^2,*, HUIQIN LIU^2,*

Oncology Research, Vol.33, No.6, pp. 1505-1505, 2025, DOI:10.32604/or.2024.056768 - 29 May 2025

Abstract This article has no abstract. More >

GUANTING PANG^1,5,#, YAOHAN LI^2,5,#, QIWEN SHI³, JINGKUI TIAN⁵, HANMEI LOU^4,5,*, YUE FENG^4,5,*

Oncology Research, Vol.33, No.4, pp. 821-836, 2025, DOI:10.32604/or.2024.053772 - 19 March 2025

Abstract Immunotherapies have demonstrated notable clinical benefits in the treatment of cervical cancer (CC). However, the development of therapeutic resistance and diverse adverse effects in immunotherapy stem from complex interactions among biological processes and factors within the tumor immune microenvironment (TIME). Advanced omic technologies offer novel insights into a more expansive and thorough layer of the TIME. Furthermore, integrating multidimensional omics within the frameworks of systems biology and computational methodologies facilitates the generation of interpretable data outputs to characterize the clinical and biological trajectories of tumor behavior. In this review, we present advanced omics technologies that More >